Longitudinal Monitoring of Plasma Circulating Tumour DNA Enables the Prediction of Early Relapse in Patients with Non-Hodgkin Lymphoma: A Case Series

Growing evidence now suggests that circulating tumour DNA (ctDNA) has great potential as a non-invasive biomarker for disease monitoring, since ctDNA carries tumour-specific modifications. In particular, monitoring ctDNA has important implications for identifying patients with haematological maligna...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hongyan Ji, Xiaolu Long, Jia Gu, Jin Jin, Xia Mao, Zhiqiong Wang, Heng Ma, Liting Chen
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	B-cell non-Hodgkin lymphoma circulating tumour DNA liquid biopsy relapse droplet digital PCR Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8018f6fc785544dda79cd281b01f0057
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8018f6fc785544dda79cd281b01f0057
record_format	dspace
spelling	oai:doaj.org-article:8018f6fc785544dda79cd281b01f00572021-11-25T17:21:13ZLongitudinal Monitoring of Plasma Circulating Tumour DNA Enables the Prediction of Early Relapse in Patients with Non-Hodgkin Lymphoma: A Case Series10.3390/diagnostics111120552075-4418https://doaj.org/article/8018f6fc785544dda79cd281b01f00572021-11-01T00:00:00Zhttps://www.mdpi.com/2075-4418/11/11/2055https://doaj.org/toc/2075-4418Growing evidence now suggests that circulating tumour DNA (ctDNA) has great potential as a non-invasive biomarker for disease monitoring, since ctDNA carries tumour-specific modifications. In particular, monitoring ctDNA has important implications for identifying patients with haematological malignancies at clinical risk of disease progression. We hereby describe three patients with B-cell non-Hodgkin lymphoma and investigate the clinical value of sequential ctDNA profiling for the early detection of tumour relapse. Somatic mutations in diagnostic tumour biopsy samples of these three patients were identified by applying high-throughput next-generation sequencing. Droplet digital PCR probes and primers were designed and tested for each hotspot mutation. Serial ctDNA analysis was subsequently conducted among these three patients. We found that the longitudinal monitoring of plasma ctDNA could predict for at least one month in advance compared with flow cytometry, cytology and conventional imaging modalities. Therefore, our results support liquid biopsy based on ctDNA as a non-invasive complementary modality to other detection methods for detecting early relapse and contribute to more precise management for non-Hodgkin lymphoma patients.Hongyan JiXiaolu LongJia GuJin JinXia MaoZhiqiong WangHeng MaLiting ChenMDPI AGarticleB-cell non-Hodgkin lymphomacirculating tumour DNAliquid biopsyrelapsedroplet digital PCRMedicine (General)R5-920ENDiagnostics, Vol 11, Iss 2055, p 2055 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	B-cell non-Hodgkin lymphoma circulating tumour DNA liquid biopsy relapse droplet digital PCR Medicine (General) R5-920
spellingShingle	B-cell non-Hodgkin lymphoma circulating tumour DNA liquid biopsy relapse droplet digital PCR Medicine (General) R5-920 Hongyan Ji Xiaolu Long Jia Gu Jin Jin Xia Mao Zhiqiong Wang Heng Ma Liting Chen Longitudinal Monitoring of Plasma Circulating Tumour DNA Enables the Prediction of Early Relapse in Patients with Non-Hodgkin Lymphoma: A Case Series
description	Growing evidence now suggests that circulating tumour DNA (ctDNA) has great potential as a non-invasive biomarker for disease monitoring, since ctDNA carries tumour-specific modifications. In particular, monitoring ctDNA has important implications for identifying patients with haematological malignancies at clinical risk of disease progression. We hereby describe three patients with B-cell non-Hodgkin lymphoma and investigate the clinical value of sequential ctDNA profiling for the early detection of tumour relapse. Somatic mutations in diagnostic tumour biopsy samples of these three patients were identified by applying high-throughput next-generation sequencing. Droplet digital PCR probes and primers were designed and tested for each hotspot mutation. Serial ctDNA analysis was subsequently conducted among these three patients. We found that the longitudinal monitoring of plasma ctDNA could predict for at least one month in advance compared with flow cytometry, cytology and conventional imaging modalities. Therefore, our results support liquid biopsy based on ctDNA as a non-invasive complementary modality to other detection methods for detecting early relapse and contribute to more precise management for non-Hodgkin lymphoma patients.
format	article
author	Hongyan Ji Xiaolu Long Jia Gu Jin Jin Xia Mao Zhiqiong Wang Heng Ma Liting Chen
author_facet	Hongyan Ji Xiaolu Long Jia Gu Jin Jin Xia Mao Zhiqiong Wang Heng Ma Liting Chen
author_sort	Hongyan Ji
title	Longitudinal Monitoring of Plasma Circulating Tumour DNA Enables the Prediction of Early Relapse in Patients with Non-Hodgkin Lymphoma: A Case Series
title_short	Longitudinal Monitoring of Plasma Circulating Tumour DNA Enables the Prediction of Early Relapse in Patients with Non-Hodgkin Lymphoma: A Case Series
title_full	Longitudinal Monitoring of Plasma Circulating Tumour DNA Enables the Prediction of Early Relapse in Patients with Non-Hodgkin Lymphoma: A Case Series
title_fullStr	Longitudinal Monitoring of Plasma Circulating Tumour DNA Enables the Prediction of Early Relapse in Patients with Non-Hodgkin Lymphoma: A Case Series
title_full_unstemmed	Longitudinal Monitoring of Plasma Circulating Tumour DNA Enables the Prediction of Early Relapse in Patients with Non-Hodgkin Lymphoma: A Case Series
title_sort	longitudinal monitoring of plasma circulating tumour dna enables the prediction of early relapse in patients with non-hodgkin lymphoma: a case series
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/8018f6fc785544dda79cd281b01f0057
work_keys_str_mv	AT hongyanji longitudinalmonitoringofplasmacirculatingtumourdnaenablesthepredictionofearlyrelapseinpatientswithnonhodgkinlymphomaacaseseries AT xiaolulong longitudinalmonitoringofplasmacirculatingtumourdnaenablesthepredictionofearlyrelapseinpatientswithnonhodgkinlymphomaacaseseries AT jiagu longitudinalmonitoringofplasmacirculatingtumourdnaenablesthepredictionofearlyrelapseinpatientswithnonhodgkinlymphomaacaseseries AT jinjin longitudinalmonitoringofplasmacirculatingtumourdnaenablesthepredictionofearlyrelapseinpatientswithnonhodgkinlymphomaacaseseries AT xiamao longitudinalmonitoringofplasmacirculatingtumourdnaenablesthepredictionofearlyrelapseinpatientswithnonhodgkinlymphomaacaseseries AT zhiqiongwang longitudinalmonitoringofplasmacirculatingtumourdnaenablesthepredictionofearlyrelapseinpatientswithnonhodgkinlymphomaacaseseries AT hengma longitudinalmonitoringofplasmacirculatingtumourdnaenablesthepredictionofearlyrelapseinpatientswithnonhodgkinlymphomaacaseseries AT litingchen longitudinalmonitoringofplasmacirculatingtumourdnaenablesthepredictionofearlyrelapseinpatientswithnonhodgkinlymphomaacaseseries
_version_	1718412480979402752

Longitudinal Monitoring of Plasma Circulating Tumour DNA Enables the Prediction of Early Relapse in Patients with Non-Hodgkin Lymphoma: A Case Series

Ejemplares similares